跳至主要内容
临床试验/NCT07152795
NCT07152795已完成不适用

Weizmannia Coagulans BC99 Improved Intestinal Motility and Chronic Constipation Through Regulating Gut Microbiota: A Randomized, Double-blind, Placebo-controlled Trial

Wecare Probiotics Co., Ltd.1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年4月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
90
试验地点
1
主要终点
Assessing the Improvement of Chronic Constipation Symptoms Following Probiotic Intervention.

研究概览

简要总结

To investigate the clinical effects of probiotics in relieving intestinal motility and chronic constipation through regulating gut microbiota.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Chinese adults aged 18-70 years who meet the Rome IV diagnostic criteria for chronic constipation (duration of at least 6 months, with less than 3 bowel movements per week and/or Bristol Stool Scale types 1 and 2);
  • •Not using laxatives rarely leads to loose stools;
  • •The standard for irritable bowel syndrome is insufficient;
  • •Research participants (including male subjects) who have no family planning within 14 days prior to screening and voluntarily take effective contraceptive measures within 6 months after the end of the trial;
  • •Patients capable of understanding the clinical study and willing to comply with the study requirements and procedures;
  • •Subjects who have signed the informed consent form. -

排除标准

  • •(1) The use of probiotics, prebiotics, or antibiotics within 2 weeks of enrollment; (2) Regular use of a high-fiber diet, as measured by the recommended food score (RFS); (3) Regular use of medications affecting bowel habits, such as irritable bowel syndrome, functional bloating, and functional diarrhea; (4) Currently have, or have had in the past 2 years, any gastrointestinal conditions such as: Crohn's disease, celiac disease, Ulcerative colitis, Malignant tumor of the colon; (5) Medical history of cardiovascular, liver, or renal diseases; alcoholics; (6) Hypersensitivity to probiotics or the ingredients used in this study; (7) Pregnancy or breastfeeding; (8) Participation in another clinical trial in the 3 months before enrollment.

研究组 & 干预措施

Placebo Group

Placebo Comparator

Participants receive one sachet per day containing maltodextrin only, serving as the placebo(Week 0 to Week8).

干预措施: Placebo (Dietary Supplement)

Probiotic Group

Experimental

Participants receive one sachet per day containing probiotic BC99 and maltodextrin (Week 0 to Week8).

干预措施: Probiotic (Dietary Supplement)

结局指标

主要结局

Assessing the Improvement of Chronic Constipation Symptoms Following Probiotic Intervention.

时间窗: 8 weeks

Constipation symptoms are measured using Bristol Stool Form Scale, where 1 and 2 indicate constipation with hard stools, 3 and 4 show normal conditions with ideal stool form, and 5, 6, and 7 suggest diarrhea with stools becoming softer to watery.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验